X-Linked Myotubular Myopathy (XLMTM) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: X5C5E4B82727EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'X-Linked Myotubular Myopathy (XLMTM) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted X-Linked Myotubular Myopathy (XLMTM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

X-Linked Myotubular Myopathy (XLMTM) Understanding

The DelveInsight X-Linked Myotubular Myopathy (XLMTM) epidemiology report gives a thorough understanding of the X-Linked Myotubular Myopathy (XLMTM) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for X-Linked Myotubular Myopathy (XLMTM) in the US, Europe, and Japan. The report covers the detailed information of the X-Linked Myotubular Myopathy (XLMTM) epidemiology scenario in seven major countries (US, EU5, and Japan).

X-Linked Myotubular Myopathy (XLMTM) Epidemiology Perspective by DelveInsight

The X-Linked Myotubular Myopathy (XLMTM) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The X-Linked Myotubular Myopathy (XLMTM) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The X-Linked Myotubular Myopathy (XLMTM) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

X-Linked Myotubular Myopathy (XLMTM) Detailed Epidemiology Segmentation

The X-Linked Myotubular Myopathy (XLMTM) epidemiology covered in the report provides historical as well as forecasted X-Linked Myotubular Myopathy (XLMTM) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight X-Linked Myotubular Myopathy (XLMTM) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The X-Linked Myotubular Myopathy (XLMTM) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The X-Linked Myotubular Myopathy (XLMTM) Epidemiology Report and Model provide an overview of the global trends of X-Linked Myotubular Myopathy (XLMTM) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of X-Linked Myotubular Myopathy (XLMTM) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of X-Linked Myotubular Myopathy (XLMTM)
• The report provides the segmentation of the X-Linked Myotubular Myopathy (XLMTM) epidemiology

Report Highlights

• 11-year Forecast of X-Linked Myotubular Myopathy (XLMTM) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of X-Linked Myotubular Myopathy (XLMTM)
• Cases of X-Linked Myotubular Myopathy (XLMTM) by Mutation Types
• X-Linked Myotubular Myopathy (XLMTM) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to X-Linked Myotubular Myopathy (XLMTM)?
• What are the key findings pertaining to the X-Linked Myotubular Myopathy (XLMTM) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of X-Linked Myotubular Myopathy (XLMTM) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of X-Linked Myotubular Myopathy (XLMTM)?
• What are the currently available treatments of X-Linked Myotubular Myopathy (XLMTM)?

Reasons to buy

The X-Linked Myotubular Myopathy (XLMTM) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global X-Linked Myotubular Myopathy (XLMTM) market
• Quantify patient populations in the global X-Linked Myotubular Myopathy (XLMTM) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for X-Linked Myotubular Myopathy (XLMTM) therapeutics in each of the markets covered
• Understand the magnitude of X-Linked Myotubular Myopathy (XLMTM) population by its epidemiology
• The X-Linked Myotubular Myopathy (XLMTM) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF X-LINKED MYOTUBULAR MYOPATHY (XLMTM)

3. X-LINKED MYOTUBULAR MYOPATHY (XLMTM): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. X-Linked Myotubular Myopathy (XLMTM) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. X-Linked Myotubular Myopathy (XLMTM) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. X-Linked Myotubular Myopathy (XLMTM) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. X-Linked Myotubular Myopathy (XLMTM) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. X-Linked Myotubular Myopathy (XLMTM) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. X-Linked Myotubular Myopathy (XLMTM) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. X-Linked Myotubular Myopathy (XLMTM) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. X-Linked Myotubular Myopathy (XLMTM) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. X-Linked Myotubular Myopathy (XLMTM) Treatment and Management
6.2. X-Linked Myotubular Myopathy (XLMTM) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: X-Linked Myotubular Myopathy (XLMTM) Epidemiology in 7MM (2019-2032)
Table 2: X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: X-Linked Myotubular Myopathy (XLMTM) Epidemiology in the United States (2019-2032)
Table 4: X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: X-Linked Myotubular Myopathy (XLMTM) Epidemiology in Germany (2019-2032)
Table 6: X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: X-Linked Myotubular Myopathy (XLMTM) Epidemiology in France (2019-2032)
Table 8: X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: X-Linked Myotubular Myopathy (XLMTM) Epidemiology in Italy (2019-2032)
Table 10: X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: X-Linked Myotubular Myopathy (XLMTM) Epidemiology in Spain (2019-2032)
Table 12: X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: X-Linked Myotubular Myopathy (XLMTM) Epidemiology in the United Kingdom (2019-2032)
Table 14: X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: X-Linked Myotubular Myopathy (XLMTM) Epidemiology in Japan (2019-2032)
Table 16: X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 X-Linked Myotubular Myopathy (XLMTM) Epidemiology in 7MM (2019-2032)
Figure 2 X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 X-Linked Myotubular Myopathy (XLMTM) Epidemiology in the United States (2019-2032)
Figure 4 X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 X-Linked Myotubular Myopathy (XLMTM) Epidemiology in Germany (2019-2032)
Figure 6 X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 X-Linked Myotubular Myopathy (XLMTM) Epidemiology in France (2019-2032)
Figure 8 X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 X-Linked Myotubular Myopathy (XLMTM) Epidemiology in Italy (2019-2032)
Figure 10 X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 X-Linked Myotubular Myopathy (XLMTM) Epidemiology in Spain (2019-2032)
Figure 12 X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 X-Linked Myotubular Myopathy (XLMTM) Epidemiology in the United Kingdom (2019-2032)
Figure 14 X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 X-Linked Myotubular Myopathy (XLMTM) Epidemiology in Japan (2019-2032)
Figure 16 X-Linked Myotubular Myopathy (XLMTM) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report